GPPC Says HHS Committee Fails to Address FDA's 'Arbitrary' Oversight of Genetic Tests | GenomeWeb
NEW YORK (GenomeWeb News) - The US Food and Drug Administration’s regulatory approach toward laboratory-developed tests unfairly favors some manufacturers, and this imbalance was not sufficiently discussed during a recent meeting of the HHS Secretary’s Advisory Committee for Genetics, Health, and Society, according to Kathy Hudson, director of Johns Hopkins University’s Genetic Public Policy Center.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.